[go: up one dir, main page]

AU2002218167A1 - N-phenyl-2-pyrimidine-amine derivatives - Google Patents

N-phenyl-2-pyrimidine-amine derivatives

Info

Publication number
AU2002218167A1
AU2002218167A1 AU2002218167A AU1816702A AU2002218167A1 AU 2002218167 A1 AU2002218167 A1 AU 2002218167A1 AU 2002218167 A AU2002218167 A AU 2002218167A AU 1816702 A AU1816702 A AU 1816702A AU 2002218167 A1 AU2002218167 A1 AU 2002218167A1
Authority
AU
Australia
Prior art keywords
pyrimidine
phenyl
amine derivatives
preparation
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218167A
Inventor
Werner Breitenstein
Hans Michael Buerger
Giorgio Caravatti
Margaret Amelia Cudd
Paul William Manley
Juerg Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9899367&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002218167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2002218167A1 publication Critical patent/AU2002218167A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

The invention relates to N-phenyl-2-pyrimidine-amine derivatives of formula I wherein the substituents are defined as indicated in the description, to processes for the preparation thereof, to medicaments comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
AU2002218167A 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives Abandoned AU2002218167A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0022438.6A GB0022438D0 (en) 2000-09-13 2000-09-13 Organic Compounds
GB0022438 2000-09-13
PCT/EP2001/010503 WO2002022597A1 (en) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Publications (1)

Publication Number Publication Date
AU2002218167A1 true AU2002218167A1 (en) 2002-03-26

Family

ID=9899367

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218167A Abandoned AU2002218167A1 (en) 2000-09-13 2001-09-11 N-phenyl-2-pyrimidine-amine derivatives

Country Status (13)

Country Link
US (3) US7081532B2 (en)
EP (1) EP1322634B1 (en)
JP (1) JP2004509111A (en)
CN (2) CN1872850A (en)
AT (1) ATE452129T1 (en)
AU (1) AU2002218167A1 (en)
BR (1) BR0113838A (en)
CA (2) CA2687476A1 (en)
DE (1) DE60140814D1 (en)
ES (1) ES2336891T3 (en)
GB (1) GB0022438D0 (en)
PT (1) PT1322634E (en)
WO (1) WO2002022597A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
EP1408978A4 (en) * 2001-06-21 2005-07-13 Ariad Pharma Inc Novel phenylamino-pyrimidines and uses thereof
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
RU2315043C2 (en) * 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Amide derivative, pharmaceutical composition and therapeutic agents based on thereof
DE60313339T2 (en) * 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. PROTEIN TYROSINE KINASE INHIBITORS
CA2439440A1 (en) 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
AU2003273675A1 (en) * 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
WO2004099186A1 (en) * 2003-05-06 2004-11-18 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
WO2004108699A1 (en) * 2003-06-06 2004-12-16 Natco Pharma Limited Process for the preparation of the anti-cancer drug imatinib and its analogues
US20060293340A1 (en) * 2003-06-13 2006-12-28 Novartis Ag 2-Aminopyrimidine derivatives as raf kinase inhibitors
ES2651615T3 (en) * 2003-12-25 2018-01-29 Nippon Shinyaku Co., Ltd. Amidoderivative and medication
JPWO2005063720A1 (en) * 2003-12-25 2007-07-19 日本新薬株式会社 Amide derivatives and pharmaceuticals
PE20051096A1 (en) * 2004-02-04 2006-01-23 Novartis Ag SALT FORMS OF 4- (4-METHYLPIPERAZIN-1-ILMETHYL) -N- [4-METHYL-3- (4-PYRIDIN-3-IL) PYRIMIDIN-2-ILAMINO) PHENYL] -BENZAMIDE
WO2006017353A2 (en) * 2004-07-13 2006-02-16 GOVERNMENT OF THE UNITED STATES, as represented byTHE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of viral infections
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) * 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
EP1786799B1 (en) 2004-09-09 2012-07-04 Natco Pharma Limited Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
CN1972917B (en) * 2004-12-31 2010-08-25 孙飘扬 Aminopyrimidine compound and its salt, its preparation method and pharmaceutical use
CN1939910A (en) 2004-12-31 2007-04-04 孙飘扬 Amino-metadiazine compound and its salt, its preparation and pharmaceutical use
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
ATE476183T1 (en) * 2005-06-23 2010-08-15 Novartis Ag METHOD FOR TREATING SOLID TUMORS INCLUDING ADMINISTRATION OF A COMBINATION OF IMATINIB AND AN EFFLUX PUMP INHIBITOR
KR100674813B1 (en) * 2005-08-05 2007-01-29 일양약품주식회사 N-phenyl-2-pyrimidine-amine derivatives and preparation method thereof
EP1928236B1 (en) * 2005-09-27 2011-11-23 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
US8067421B2 (en) * 2006-04-27 2011-11-29 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
US7977348B2 (en) * 2006-04-27 2011-07-12 Sicor Inc. Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
UA93548C2 (en) 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
EP2068835A2 (en) * 2006-09-01 2009-06-17 Teva Pharmaceutical Industries Ltd. Imatinib compositions
EP2471529A3 (en) * 2006-09-05 2012-10-10 Emory University Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof
KR20090061055A (en) * 2006-10-26 2009-06-15 시코르, 인크. Crystalline and amorphous imatinib bases, imatinib mesylate and methods for their preparation
EP1988089A1 (en) 2006-10-26 2008-11-05 Sicor, Inc. Imatinib base, and imatinib mesylate and processes for preparation thereof
CA2673683C (en) 2007-01-11 2014-07-29 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
US20090012296A1 (en) * 2007-05-29 2009-01-08 Alexandr Jegorov Processes for the preparation of crystalline form beta of imatinib mesylate
TWI433677B (en) 2007-06-04 2014-04-11 Avila Therapeutics Inc Heterocyclic compounds and uses thereof
RU2455288C2 (en) 2007-08-22 2012-07-10 Айрм Ллк Compounds and compositions of 5-(4-(halogenalkoxy)phenyl)pyrimidin-2-amine as kinase inhibitors
JP5303557B2 (en) 2007-08-22 2013-10-02 アイアールエム・リミテッド・ライアビリティ・カンパニー 2-Heteroarylamino-pyrimidine derivatives which are kinase inhibitors
EP2086520A1 (en) * 2007-09-25 2009-08-12 Teva Pharmaceutical Industries Ltd. Imatinib compositions
WO2009079797A1 (en) 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
EP2240175B1 (en) * 2008-02-11 2013-01-02 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Compounds with mdr1-inverse activity
NZ587589A (en) 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
LT2300013T (en) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
AU2009262214B9 (en) * 2008-06-27 2015-04-30 Indiana University Research And Technology Corporation Materials and methods for suppressing and/or treating neurofibroma and related tumors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN101417995B (en) * 2008-11-21 2012-06-06 陈依军 Phenoxy pyrimidine derivates and preparation method and use thereof
RU2011140238A (en) 2009-04-15 2013-05-20 Астразенека Аб Imidazole-substituted pyrimidines useful in the treatment of diseases associated with kinase-3 glycogen synthase, such as Alzheimer's disease
US8816077B2 (en) 2009-04-17 2014-08-26 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
US8530492B2 (en) * 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
CN102212057B (en) * 2011-04-13 2013-11-27 合肥工业大学 A kind of carboxylic acid non-steroidal anti-inflammatory drug derivative and its preparation method and application
CA2832504C (en) 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
CN102796110B (en) * 2011-05-23 2016-03-30 复旦大学 Aniline pyrimidine compound and its production and use
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN103044394A (en) * 2012-12-20 2013-04-17 北京理工大学 Phenyl aminopyrimidine derivant and preparation method and application thereof
CN103058935B (en) * 2013-01-15 2015-05-06 四川大学 Pyrimidine compound as well as preparation method and use for same
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105859683B (en) * 2016-04-11 2018-09-28 连云港恒运药业有限公司 The high-purity technical preparation process of Imatinib
CN107805240A (en) * 2016-09-08 2018-03-16 中国科学院合肥物质科学研究院 A kind of new PDGFR kinase inhibitors and application thereof
CN107652266A (en) * 2017-10-27 2018-02-02 上海应用技术大学 One kind targeting EGFR-TK micromolecular inhibitor and its application
EP3935057A4 (en) * 2019-03-05 2023-03-01 Hongyi & Associates LLC COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AND CANCERS
CN110078708B (en) * 2019-05-08 2020-12-11 东南大学 Smo/Bcr-Abl dual-targeted inhibitor and its synthesis method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
CA2416274A1 (en) 2002-03-21
CN1872850A (en) 2006-12-06
ATE452129T1 (en) 2010-01-15
CN100406452C (en) 2008-07-30
HK1057752A1 (en) 2004-04-16
US20070265292A1 (en) 2007-11-15
US7329661B2 (en) 2008-02-12
EP1322634A1 (en) 2003-07-02
PT1322634E (en) 2010-02-22
WO2002022597A1 (en) 2002-03-21
ES2336891T3 (en) 2010-04-19
US20040102453A1 (en) 2004-05-27
US7312216B2 (en) 2007-12-25
US20060223818A1 (en) 2006-10-05
DE60140814D1 (en) 2010-01-28
CN1525967A (en) 2004-09-01
GB0022438D0 (en) 2000-11-01
CA2687476A1 (en) 2002-03-21
BR0113838A (en) 2003-06-03
EP1322634B1 (en) 2009-12-16
US7081532B2 (en) 2006-07-25
CA2416274C (en) 2011-01-04
JP2004509111A (en) 2004-03-25

Similar Documents

Publication Publication Date Title
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
WO2003053368A3 (en) Chalcone derivatives and their use to treat diseases
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
PT1416935E (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
TW200510392A (en) Chemical compounds
MXPA04000577A (en) Dolastatin 10 derivatives.
MXPA04004601A (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments.
GB0112348D0 (en) Compounds
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
TW200505452A (en) Chemical compounds
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE233754T1 (en) DIPHENYL-PIPERIDINE DERIVATIVES
BG106155A (en) Novel derivatives and analogues of galanthamin
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
UA83832C2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2001266019A1 (en) 2-amino-3-hydroxy-4-tert-leucyl-amino-5-phenyl-pentanoic acid amide derivatives
TW200504051A (en) Novel acridine derivatives and their use as medicaments
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
PE20030236A1 (en) DERIVATIVES OF BENZIMIDAZOLE 1-ARIL-2-N, S- OR O-SUBSTITUTES, OBTAINING DRUGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES
WO2004108094A3 (en) Sulfonamide-substituted chalcone derivatives and their use to treat diseases
ATE346080T1 (en) STEROID COMPOUNDS WITH ANTI-TUMORAL EFFECT